BSE
ALKEM

Alkem Laboratories Ltd

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Alkem Laboratories Ltd Stock Price

Vitals

Today's Low:
₹3620.05
Today's High:
₹3674.05
Open Price:
₹3620.05
52W Low:
₹2828.3415
52W High:
₹4270.9502
Prev. Close:
₹3631.05
Volume:
12956

Company Statistics

Market Cap.:
₹443.60 billion
Book Value:
756.517
Revenue TTM:
₹119.91 billion
Operating Margin TTM:
12.59%
Gross Profit TTM:
₹65.79 billion
Profit Margin:
9.54%
Return on Assets TTM:
5.93%
Return on Equity TTM:
11.01%

Company Profile

Alkem Laboratories Ltd had its IPO on under the ticker symbol ALKEM.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Alkem Laboratories Ltd has a staff strength of 16,871 employees.

Stock update

Shares of Alkem Laboratories Ltd opened at ₹3620.05 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹3620.05 - ₹3674.05, and closed at ₹3635.05.

This is a +0.11% increase from the previous day's closing price.

A total volume of 12,956 shares were traded at the close of the day’s session.

In the last one week, shares of Alkem Laboratories Ltd have slipped by -0.4%.

Alkem Laboratories Ltd's Key Ratios

Alkem Laboratories Ltd has a market cap of ₹443.60 billion, indicating a price to book ratio of 4.105 and a price to sales ratio of 3.5279.

In the last 12-months Alkem Laboratories Ltd’s revenue was ₹119.91 billion with a gross profit of ₹65.79 billion and an EBITDA of ₹17.79 billion. The EBITDA ratio measures Alkem Laboratories Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alkem Laboratories Ltd’s operating margin was 12.59% while its return on assets stood at 5.93% with a return of equity of 11.01%.

In Q2, Alkem Laboratories Ltd’s quarterly earnings growth was a positive 124.5% while revenue growth was a positive 15.2%.

Alkem Laboratories Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
45.1576
PEG

Its diluted EPS in the last 12-months stands at ₹82.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alkem Laboratories Ltd’s profitability.

Alkem Laboratories Ltd stock is trading at a EV to sales ratio of 3.4305 and a EV to EBITDA ratio of 22.2155. Its price to sales ratio in the trailing 12-months stood at 3.5279.

Alkem Laboratories Ltd stock pays annual dividends of ₹25 per share, indicating a yield of 0.53% and a payout ratio of 26.15%.

Balance sheet and cash flow metrics

Total Assets
₹137.57 billion
Total Liabilities
₹37.07 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
26.15%

Alkem Laboratories Ltd ended 2024 with ₹137.57 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹137.57 billion while shareholder equity stood at ₹90.45 billion.

Alkem Laboratories Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹37.07 billion in other current liabilities, 239100000.00 in common stock, ₹90.21 billion in retained earnings and ₹4.13 billion in goodwill. Its cash balance stood at ₹2.74 billion and cash and short-term investments were ₹31.24 billion. The company’s total short-term debt was ₹13,071,500,000 while long-term debt stood at ₹0.00.

Alkem Laboratories Ltd’s total current assets stands at ₹87.30 billion while long-term investments were ₹0 and short-term investments were ₹5.07 billion. Its net receivables were ₹21.32 billion compared to accounts payable of ₹11.65 billion and inventory worth ₹26.08 billion.

In 2024, Alkem Laboratories Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Alkem Laboratories Ltd paid ₹0.26 in dividends in 2024.

Other key metrics

Current Trading Price
₹3635.05
52-Week High
₹4270.9502
52-Week Low
₹2828.3415
Analyst Target Price

Alkem Laboratories Ltd stock is currently trading at ₹3635.05 per share. It touched a 52-week high of ₹4270.9502 and a 52-week low of ₹4270.9502. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹3753.53 and 200-day moving average was ₹3350.08 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 7391.7% of the company’s stock are held by insiders while 1931.9% are held by institutions.

Frequently Asked Questions About Alkem Laboratories Ltd

The stock symbol (also called stock or share ticker) of Alkem Laboratories Ltd is ALKEM

The IPO of Alkem Laboratories Ltd took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
₹8.51
-2.59
-23.33%
₹27
0
0%
₹1.36
-0.09
-6.21%
₹15.96
0
0%
Aenza SAA (AENZ)
₹2.4
-0.07
-2.64%
₹4.73
-0.17
-3.47%
₹143.55
-7.55
-5%
₹2.32
0.01
+0.43%
₹10.17
0
-4.33%
₹15.15
-0.65
-4.11%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India.

Address